Zie ook literatuurlijst van niet-toxische middelen en behandelingen specifiek bij longkanker van arts-bioloog drs. Engelbert Valstar

24 juli 2023: zie ook dit artikel: https://kanker-actueel.nl/circulerend-tumor-dna-ctdna-voorspelt-ziekteprogressie-bij-patienten-met-niet-kleincellige-longkanker-egfr-mutatie-die-worden-behandeld-met-tyrosinekinaseremmers.html

30 maart 2023: zie ook dit artikel: https://kanker-actueel.nl/circulerend-tumor-dna-ctdna-regelmatig-meten-en-combineren-met-een-weefselanalyse-biopt-geeft-beduidend-meer-informatie-over-veranderde-mutaties-bij-patienten-met-uitgezaaide-gevorderde-kleincellige-longkanker.html

24 juli 2023: Bron: Nature 21 november 2021

Meting van circulerend tumor-DNA (ctDNA) is een sterke voorspeller van al of niet een optreden van een recidief bij patiënten met niet-kleincellige longkanker. Wanneer het ctDNA een positieve uitslag geeft van overgebleven kankercellen dan is een verwacht recidief een heel stuk meer dan voor de patiënten die negatief scoorden in de ctDNA testen. ctDNA metingen werden gedaan direct na de operatie en gedurende de behandeling met chemotherapie en ook werden die ctDNA metingen gedaan bij patiënten die geen chemotherapie hadden gehad. 

Dat blijkt uit een Chinese studie bij 103 operabele longkankerpatiënten stadium II/III waarbij gedurende een bepaalde periode regelmatig ctDNA is getest. Bij stadium II-III-patiënten heeft de postoperatieve ctDNA-positieve groep baat bij aanvullende chemotherapie als de ctDNA test positief was, terwijl ctDNA-negatieve patiënten een laag risico op een recidief hebben, ongeacht of er wel of geen chemotherapie is toegediend. Tijdens ziekte controle gaat ctDNA-positiviteit mediaan 88 dagen vooraf aan een radiologisch aantoonbaar recidief.

In onderstaande grafiek de verschillen grafisch weergegeven:

figure 2


a Kaplan–Meier curve of recurrence-free survival (RFS) in patients stratified by postsurgical ctDNA status. p-value was calculated by the log-rank test. b Kaplan–Meier curve of RFS in patients stratified by post-ACT ctDNA status. p-value was calculated by the log-rank test. c Kaplan–Meier curve of RFS in stage II–III patients stratified by both ACT treatment and postsurgical ctDNA status. p-value was calculated by the log-rank test for each comparison without adjustments. d Kaplan–Meier curve of RFS in patients stratified by longitudinal ctDNA status. p-value was calculated by the log-rank test.

Het studieverslag, gepubliceerd in Nature geeft een gedetailleerd beeld van hoe is er getest en hoe de onderzoekers de verkregen gegevens hebben toegepast in deze studie. En hoe een ctDNA test van waarde kan zijn voor een vervolg behandeling na de operatie. Of juist geen behandeling om overbehandeling te voorkomen.

Het volledige studierapport is gratis in te zien. Klik op de titel voor het volledige studierapport: 

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC

Nature Communications volume 12, Article number: 6770 (2021) Cite this article


Abstract

Accurately evaluating minimal residual disease (MRD) could facilitate early intervention and personalized adjuvant therapies. Here, using ultradeep targeted next-generation sequencing (NGS), we evaluate the clinical utility of circulating tumor DNA (ctDNA) for dynamic recurrence risk and adjuvant chemotherapy (ACT) benefit prediction in resected non-small cell lung cancer (NSCLC). Both postsurgical and post-ACT ctDNA positivity are significantly associated with worse recurrence-free survival. In stage II-III patients, the postsurgical ctDNA positive group benefit from ACT, while ctDNA negative patients have a low risk of relapse regardless of whether or not ACT is administered. During disease surveillance, ctDNA positivity precedes radiological recurrence by a median of 88 days. Using joint modeling of longitudinal ctDNA analysis and time-to-recurrence, we accurately predict patients’ postsurgical 12-month and 15-month recurrence status. Our findings reveal longitudinal ctDNA analysis as a promising tool to detect MRD in NSCLC, and we show pioneering work of using postsurgical ctDNA status to guide ACT and applying joint modeling to dynamically predict recurrence risk, although the results need to be further confirmed in future studies.

Data availability

All raw targeted DNA-sequencing data have been deposited in the National Genomics Data Center (NGDC) under the accession code HRA001346. The deposited and publicly available data are compliant with the regulations of the Ministry of Science and Technology of the People’s Republic of China. The raw sequencing data contain information unique to individuals and are available under controlled access. Access to the data can be requested by completing the application form via GSA-Human System and is granted by the corresponding Data Access Committee. Additional guidance can be found at the GSA-Human System website [https://ngdc.cncb.ac.cn/gsa-human/document/GSA-Human_Request_Guide_for_Users_us.pdf]. Data used for survival analysis and joint model construction and evaluation are publicly available at https://github.com/cancer-oncogenomics/ctDNA-dynamic-prediction-lung-cancer. All specific mutation genomic locations and allele frequencies are available in Supplementary Data 2. Source data are provided with this paper.

Code availability

All analyses were performed using R version 4.0.2. R package survival (version 3.2-10) was used for survival analysis. R package JMbayes (version 0.8-85) was used for the construction and evaluation of joint models and cox models. Reference scripts to reproduce the results of this study is available at https://github.com/cancer-oncogenomics/ctDNA-dynamic-prediction-lung-cancer.

References

  1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).

    Article Google Scholar 

  2. Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E. & Adjei, A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584–594 (2008).

    Article Google Scholar 

  3. Postmus, P. E. et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28, iv1–iv21 (2017).

    Article CAS Google Scholar 

  4. NCCN Clinical Practice Guidelines in Oncology (version 8). National Comprehensive Cancer Network (2020).

  5. Chao, M. & Gibbs, P. Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer. J. Clin. Oncol. 27, e279–e280 (2009).

    Article Google Scholar 

  6. Huang, K. et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)–can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother. Oncol. 102, 335–342 (2012).

    Article Google Scholar 

  7. Group NM-aC. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375, 1267–1277 (2010).

    Article Google Scholar 

  8. Bradbury, P. et al. Postoperative adjuvant systemic therapy in completely resected non-small-cell lung cancer: a systematic review. Clin. Lung Cancer 18, 259–273 (2017).

    Article Google Scholar 

  9. Cortés, Á. A., Urquizu, L. C. & Cubero, J. H. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl. Lung Cancer Res. 4, 191 (2015).

    Google Scholar 

  10. Garcia-Murillas, I. et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 7, 302ra133 (2015).

    Article Google Scholar 

  11. Coombes, R. C. et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin. Cancer Res. 25, 4255–4263 (2019).

    Article CAS Google Scholar 

  12. Reinert, T. et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 5, 1124–1131 (2019).

  13. Yang, J. et al. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis. 11, 346 (2020).

    Article CAS Google Scholar 

  14. Christensen, E. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clin. Oncol. 37, 1547–1557 (2019).

    Article CAS Google Scholar 

  15. Chaudhuri, A. A. et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Disco. 7, 1394–1403 (2017).

    Article CAS Google Scholar 

  16. Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446–451 (2017).

    Article ADS CAS Google Scholar 

  17. Hellmann, M. D. et al. Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L) 1 blockade in NSCLC. Clin. Cancer Res. 26, 2849–2858 (2020).

  18. Ibrahim, J. G., Chen, M.-H. & Sinha, D. Bayesian methods for joint modeling of longitudinal and survival data with applications to cancer vaccine trials. Stat. Sin. 14, 863–883 (2004).

  19. Li, K., Furr-Stimming, E., Paulsen, J. S. & Luo, S., Group P-HIotHS. Dynamic prediction of motor diagnosis in Huntington’s disease using a joint modeling approach. J. Huntingt. Dis. 6, 127–137 (2017).

    Article CAS Google Scholar 

  20. Ibrahim, J. G., Chu, H. & Chen, L. M. Basic concepts and methods for joint models of longitudinal and survival data. J. Clin. Oncol. 28, 2796–2801 (2010).

    Article Google Scholar 

  21. Asar, O., Ritchie, J., Kalra, P. A. & Diggle, P. J. Joint modelling of repeated measurement and time-to-event data: an introductory tutorial. Int. J. Epidemiol. 44, 334–344 (2015).

    Article Google Scholar 

  22. Zhang, X. C. et al. Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nat. Commun. 10, 1772 (2019).

    Article ADS CAS Google Scholar 

  23. Chen, L. M., Ibrahim, J. G. & Chu, H. Sample size and power determination in joint modeling of longitudinal and survival data. Stat. Med. 30, 2295–2309 (2011).

    Article MathSciNet Google Scholar 

  24. Van Houwelingen, H. C. Dynamic prediction by landmarking in event history analysis. Scand. J. Stat. 34, 70–85 (2007).

    Article MathSciNet Google Scholar 

  25. Halabi, S., Li, C. & Luo, S. Developing and validating risk assessment models of clinical outcomes in modern oncology. JCO Precis Oncol. 3, https://doi.org/10.1200/PO.19.00068 (2019).

  26. Rizopoulos, D., Molenberghs, G. & Lesaffre, E. M. Dynamic predictions with time‐dependent covariates in survival analysis using joint modeling and landmarking. Biometrical J. 59, 1261–1276 (2017).

    Article MathSciNet Google Scholar 

  27. Huang, Y., Li, W., Macheret, F., Gabriel, R. A. & Ohno-Machado, L. A tutorial on calibration measurements and calibration models for clinical prediction models. J. Am. Med. Inform. Assoc. 27, 621–633 (2020).

    Article Google Scholar 

  28. Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548–554 (2014).

    Article CAS Google Scholar 

  29. Abbosh. C. et al. Abstract CT023: Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: a lung TRACERx study. AACR (2020).

  30. Chen, K. et al. Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC). Clin. Cancer Res. 25, 7058–7067 (2019).

    Article CAS Google Scholar 

  31. Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra224–224ra224 (2014).

    Article Google Scholar 

  32. Razavi, P. et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat. Med. 25, 1928–1937 (2019).

    Article CAS Google Scholar 

  33. Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472–1478 (2014).

    Article CAS Google Scholar 

  34. McKerrell, T. et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 10, 1239–1245 (2015).

    Article CAS Google Scholar 

  35. Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014).

    Article Google Scholar 

  36. Wang, Z. et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol. 5, 696–702 (2019).

    Article Google Scholar 

  37. Zhang, S. et al. Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study. Cancer Commun. 38, 28 (2018).

    Article Google Scholar 

  38. Park, C. K., Cho, H. J., Choi, Y. D., Oh, I. J. & Kim, Y. C. A phase II trial of osimertinib in the second-line treatment of non-small cell lung cancer with the EGFR T790M mutation, detected from circulating tumor DNA: LiquidLung-O-Cohort 2. Cancer Res. Treat. 51, 777–787 (2019).

    Article CAS Google Scholar 

  39. Taieb, J. et al. Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post-hoc analysis of the PRODIGE-GERCOR IDEA-France trial. Clin. Cancer Res. 27, 5638–5646 (2021).

  40. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).

    Article CAS Google Scholar 

  41. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).

    Article CAS Google Scholar 

  42. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568–576 (2012).

    Article CAS Google Scholar 

  43. Newman, A. M. et al. FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics 30, 3390–3393 (2014).

    Article CAS Google Scholar 

  44. Rizopoulos, D. The R package JMbayes for fitting joint models for longitudinal and time-to-event data using MCMC. J. Stat. Software 72, https://doi.org/10.18637/jss.v072.i07 (2016).

Download references

Acknowledgements

We appreciate the support and participation of the physicians and patients in this study.

Author information

Author notes

  1. These authors contributed equally: Bin Qiu, Wei Guo.

Authors and Affiliations

  1. Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Bin Qiu, Wei Guo, Fan Zhang, Fang Lv, Ying Ji, Yue Peng, Fengwei Tan, Qi Xue, Shugeng Gao & Jie He

  2. Key Laboratory of Minimally Invasive Therapy Research for Lung Cancer, Chinese Academy of Medical Sciences, Beijing, China

    Bin Qiu, Wei Guo, Fengwei Tan, Qi Xue & Shugeng Gao

  3. Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China

    Xiaoxi Chen, Hua Bao, Yang Xu & Yang Shao

Contributions

B.Q. and S.G. conceived the study. B.Q., W.G., H.B., Y.S., F.T., Q.X. and S.G. provided project management and supervision. B.Q., W.G., F.Z., F.L., Y.J., Y.P. and F.T. provided or facilitated the accrual of patient samples, pathology, and/or clinical data. W.G., X.C. and H.B. performed bioinformatics and genomic analyses. B.Q., W.G., F.Z., F.L., Y.J. and Y.P. performed statistical analyses. W.G. and X.C. wrote the original draft, with input from all authors. B.Q., Y.X., H.B., S.G. and J.H. review and editing the manuscript.

Corresponding author

Correspondence to Shugeng Gao.

Ethics declarations

Competing interests

The following authors are employees of Nanjing Geneseeq Technology Inc. (Xiaoxi Chen, Hua Bao, Yang Xu, and Yang Shao). All remaining authors declare no competing interests.

Additional information

Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Source data

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

ctDNA, circulerend tumor-DNA, niet-kleincellige longkanker, voorspellende waarde, chemotherapie, minimale residuele ziekte, MRD


Plaats een reactie ...

Reageer op "ctDNA = circulerend tumor-DNA meet en voorspelt al of niet minimale overgebleven kankercellen bij patienten met niet-kleincellige longkanker en is belangrijk voor post operatieve behandeling"


Gerelateerde artikelen
 

Gerelateerde artikelen

ESMO 2024; aanbevolen abstracten >> ASCO 2024: aanbevolen abstracten >> Longkanker informatie algemeen >> Bestraling - radiotherapie >> Adagrasib met of zonder cetuximab >> Angiogenese remmer, Vadimesam, >> Alimta - Pemetrexed - goedgekeurd >> Biomarker test op EGFR en >> Selpercatinib (LOXO-292), >> Chemo bij longkanker: overzicht >>